Cargando…
Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant
Immunodeficient individuals often rely on donor-derived immunoglobulin (Ig) replacement therapy (IGRT) to prevent infections. The passive immunity obtained by IGRT is limited and reflects the state of immunity in the plasma donor population at the time of donation. The objective of the current study...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090539/ https://www.ncbi.nlm.nih.gov/pubmed/35538387 http://dx.doi.org/10.1007/s10875-022-01283-9 |
_version_ | 1784704746019356672 |
---|---|
author | Lindahl, Hannes Klingström, Jonas Da Silva Rodrigues, Rui Christ, Wanda Chen, Puran Ljunggren, Hans-Gustaf Buggert, Marcus Aleman, Soo Smith, C. I. Edvard Bergman, Peter |
author_facet | Lindahl, Hannes Klingström, Jonas Da Silva Rodrigues, Rui Christ, Wanda Chen, Puran Ljunggren, Hans-Gustaf Buggert, Marcus Aleman, Soo Smith, C. I. Edvard Bergman, Peter |
author_sort | Lindahl, Hannes |
collection | PubMed |
description | Immunodeficient individuals often rely on donor-derived immunoglobulin (Ig) replacement therapy (IGRT) to prevent infections. The passive immunity obtained by IGRT is limited and reflects the state of immunity in the plasma donor population at the time of donation. The objective of the current study was to describe how the potential of passive immunity to SARS-CoV-2 in commercial off-the-shelf Ig products used for IGRT has evolved during the pandemic. Samples were collected from all consecutive Ig batches (n = 60) from three Ig producers used at the Immunodeficiency Unit at Karolinska University Hospital from the start of the SARS-CoV-2 pandemic until January 2022. SARS-CoV-2 antibody concentrations and neutralizing capacity were assessed in all samples. In vivo relevance was assessed by sampling patients with XLA (n = 4), lacking endogenous immunoglobulin synthesis and on continuous Ig substitution, for plasma SARS-CoV-2 antibody concentration. SARS-CoV-2 antibody concentrations in commercial Ig products increased over time but remained inconsistently present. Moreover, Ig batches with high neutralizing capacity towards the Wuhan-strain of SARS-CoV-2 had 32-fold lower activity against the Omicron variant. Despite increasing SARS-CoV-2 antibody concentrations in commercial Ig products, four XLA patients on IGRT had relatively low plasma concentrations of SARS-CoV-2 antibodies with no potential to neutralize the Omicron variant in vitro. In line with this observation, three out the four XLA patients had symptomatic COVID-19 during the Omicron wave. In conclusion, 2 years into the pandemic the amounts of antibodies to SARS-CoV-2 vary considerably among commercial Ig batches obtained from three commercial producers. Importantly, in batches with high concentrations of antibodies directed against the original virus strain, protective passive immunity to the Omicron variant appears to be insufficient. |
format | Online Article Text |
id | pubmed-9090539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90905392022-05-11 Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant Lindahl, Hannes Klingström, Jonas Da Silva Rodrigues, Rui Christ, Wanda Chen, Puran Ljunggren, Hans-Gustaf Buggert, Marcus Aleman, Soo Smith, C. I. Edvard Bergman, Peter J Clin Immunol Original Article Immunodeficient individuals often rely on donor-derived immunoglobulin (Ig) replacement therapy (IGRT) to prevent infections. The passive immunity obtained by IGRT is limited and reflects the state of immunity in the plasma donor population at the time of donation. The objective of the current study was to describe how the potential of passive immunity to SARS-CoV-2 in commercial off-the-shelf Ig products used for IGRT has evolved during the pandemic. Samples were collected from all consecutive Ig batches (n = 60) from three Ig producers used at the Immunodeficiency Unit at Karolinska University Hospital from the start of the SARS-CoV-2 pandemic until January 2022. SARS-CoV-2 antibody concentrations and neutralizing capacity were assessed in all samples. In vivo relevance was assessed by sampling patients with XLA (n = 4), lacking endogenous immunoglobulin synthesis and on continuous Ig substitution, for plasma SARS-CoV-2 antibody concentration. SARS-CoV-2 antibody concentrations in commercial Ig products increased over time but remained inconsistently present. Moreover, Ig batches with high neutralizing capacity towards the Wuhan-strain of SARS-CoV-2 had 32-fold lower activity against the Omicron variant. Despite increasing SARS-CoV-2 antibody concentrations in commercial Ig products, four XLA patients on IGRT had relatively low plasma concentrations of SARS-CoV-2 antibodies with no potential to neutralize the Omicron variant in vitro. In line with this observation, three out the four XLA patients had symptomatic COVID-19 during the Omicron wave. In conclusion, 2 years into the pandemic the amounts of antibodies to SARS-CoV-2 vary considerably among commercial Ig batches obtained from three commercial producers. Importantly, in batches with high concentrations of antibodies directed against the original virus strain, protective passive immunity to the Omicron variant appears to be insufficient. Springer US 2022-05-11 2022 /pmc/articles/PMC9090539/ /pubmed/35538387 http://dx.doi.org/10.1007/s10875-022-01283-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Lindahl, Hannes Klingström, Jonas Da Silva Rodrigues, Rui Christ, Wanda Chen, Puran Ljunggren, Hans-Gustaf Buggert, Marcus Aleman, Soo Smith, C. I. Edvard Bergman, Peter Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant |
title | Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant |
title_full | Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant |
title_fullStr | Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant |
title_full_unstemmed | Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant |
title_short | Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant |
title_sort | neutralizing sars-cov-2 antibodies in commercial immunoglobulin products give patients with x-linked agammaglobulinemia limited passive immunity to the omicron variant |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090539/ https://www.ncbi.nlm.nih.gov/pubmed/35538387 http://dx.doi.org/10.1007/s10875-022-01283-9 |
work_keys_str_mv | AT lindahlhannes neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT klingstromjonas neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT dasilvarodriguesrui neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT christwanda neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT chenpuran neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT ljunggrenhansgustaf neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT buggertmarcus neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT alemansoo neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT smithciedvard neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant AT bergmanpeter neutralizingsarscov2antibodiesincommercialimmunoglobulinproductsgivepatientswithxlinkedagammaglobulinemialimitedpassiveimmunitytotheomicronvariant |